Detail akcie Journey Medical Rg online

Business Summary: Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Journey Medical Corp revenues increased 8% to $45.8M. Net loss decreased 37% to $10.2M. Revenues reflect Qbrexa segment increase of less than 1% to $19.5M. Lower net loss reflects Foreign exchange transaction losses decrease of 32% to $71K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.81 to -$0.44.